ARPARIAL 25mg / 7.5mg tablets medication leaflet

C07FX05 metoprolol + ivabradine • Cardiovascular system | Beta blocking agents, other combinations

The combination of metoprolol and ivabradine is used for the treatment of chronic heart failure and stable angina pectoris. This combination combines a beta-blocker (metoprolol) and an If channel inhibitor (ivabradine) to reduce heart rate and improve cardiac function.

Metoprolol helps reduce the heart's oxygen demand, while ivabradine lowers the heart rate without affecting myocardial contractility. This leads to better heart perfusion and reduced angina symptoms.

The medication is administered as directed by a doctor, and the dose should be adjusted based on the patient's condition. It is important to monitor heart rate during treatment to avoid severe bradycardia.

Side effects may include dizziness, fatigue, or temporary visual disturbances. Patients with severe bradycardia, severe liver impairment, or allergies to any of the medication's components should avoid its use.

General data about ARPARIAL 25mg / 7.5mg

Substance: metoprolol + ivabradine

Commercial code: W61988001

Concentration: 25mg / 7.5mg

Pharmaceutical form: tablets

Quantity: 14

Product type: generic

Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

Manufacturer: LES LABORATOIRES SERVIER INDUSTRIE - FRANTA

Holder: EGIS PHARMACEUTICALS PLC - UNGARIA

Number: 13049/2020/01

Shelf life: 30 months

Concentrations available for metoprolol + ivabradine

25mg/5mg, 25mg/7.5mg, 50mg/5mg, 50mg/7.5mg